(2E,3E)-4-乙基-2-(羟基亚胺)-5-硝基-3-己烯酰胺 | 138472-01-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (2E,3E)-4-乙基-2-(羟基亚胺)-5-硝基-3-己烯酰胺
• 英文名称: (E,2Z)-4-ethyl-2-hydroxyimino-6-methoxy-5-nitrohex-3-enamide
• CAS: 138472-01-2
• 化学式: C9H15N3O5
• 分子量: 245.23
• InChiKey: JVHDMSWCQZOZHJ-JWVBWWOWSA-N

物化性质

• 溶解度：
  DMF：>34mg/mL； DMSO：>20mg/mL；乙醇：>36mg/mL； PBS pH 7.2：>2.2 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险品标志：
  T
• 危险类别码：
  R25
• 危险品运输编号：
  UN 2811 6.1 / PGIII
• WGK Germany：
  3
• 安全说明：
  S45
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310

文献信息

• USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES
  申请人：Universiteit Gent

  公开号：EP2429298A2

  公开（公告）日：2012-03-21
• A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME
  申请人：Institut National de la Santé et de la Recherche Médicale

  公开号：EP3600373A1

  公开（公告）日：2020-02-05
• [EN] USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES<br/>[FR] UTILISATION DE NO ET DE DONNEURS DE NO POUR TERMINER LA DORMANCE CHEZ LES INVERTÉBRÉS
  申请人：UNIV GENT

  公开号：WO2010130770A9

  公开（公告）日：2011-08-04

  [EN] The present invention relates to a method for terminating dormancy in an invertebrate, wherein said invertebrate is brought in contact with nitric oxide and/or a nitric oxide donor. The method can be used in pest management of unfavourable species, in eliminating dormant stages of aquatic invertebrates in ballast water in promoting termination of dormancy in beneficial species and /or in stimulating production of live food in aquacultures.
  [FR] La présente invention concerne un procédé pour terminer la dormance chez un invertébré, ledit invertébré étant mis en contact avec du monoxyde d'azote et/ou un donneur de monoxyde d'azote. Le procédé peut être utilisé dans la gestion d'organismes nuisibles d'espèces défavorables, dans l'élimination de stades dormant d'invertébrés aquatiques dans de l'eau de ballastage, dans la promotion de la terminaison de la dormance dans des espèces bénéfiques et/ou dans la stimulation de la production de nourriture vivante dans des aquacultures.
• [EN] A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME<br/>[FR] ANTAGONISTE DE LA GNRH DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT D'UNE FEMME AFFECTÉE PAR LE SYNDROME DES OVAIRES POLYKYSTIQUES
  申请人：INST NAT SANTE RECH MED

  公开号：WO2018177746A1

  公开（公告）日：2018-10-04

  The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals.